Survival Outcomes in Patients with Non-Endometrioid Uterine Malignancies at a Tertiary Cancer Centre in North Kerala, India: A Retrospective Analysis
Background and Objectives: Non-endometrioid uterine carcinomas and sarcomas are aggressive, rare malignancies, with the exception of typically indolent low-grade endometrial stromal sarcoma (LG-ESS). This 10.25-year study reports on the relative frequency, clinical presentation and survival outcomes of these tumours from a major tertiary centre in South India. Methods: Patients diagnosed with non-endometrioid uterine malignancies between 2011 and 2021 were retrospectively analysed. Clinical features, treatment regimens, recurrence patterns and follow-up data were collected to evaluate survival and prognostic variables. Primary objectives were to assess histological distribution, clinical presentation, overall survival (OS) and relapse-free survival (RFS) across non-endometrioid epithelial and non-epithelial subtypes. Secondary objectives were to evaluate subtype-specific recurrence patterns and survival prognostic factors. Results: Out of the 925 uterine malignancies evaluated, 255 were uncommon histologies (27.6%), comprising epithelial (n=185 (72.5%): serous carcinoma (SC) n=116, carcinosarcoma (CS) n=45, clear cell carcinoma (CCC) n=20, undifferentiated/squamous cell carcinoma n=4) and non-epithelial subtypes (n=70 (27.5%): leiomyosarcoma (LMS) n=35, LG-ESS n=22 and high-grade endometrial stromal sarcoma (HG-ESS) n=10, pleomorphic sarcoma n=3). The median patient age was 59 years, with 158 patients (62%) presenting at stage I and 230 patients (90.2%) undergoing curative-intent treatment. Statistically significant survival variations were observed across both groups (p<0.05). Among epithelial malignancies (median follow-up 56 months; 95% confidence interval (CI): 47.3-64.7), five-year OS and RFS differed significantly (p=0.003 and <0.001, respectively), with the highest five-year OS and RFS noted in SC (65.5% OS, 61.2% RFS) and CCC (65.8% OS,52.5% RFS), compared to markedly inferior outcomes in CS (37.1% OS, 23.6% RFS). Stage-stratified outcomes in SCs revealed a significant difference in five-year OS between early (stage I/II) versus advanced stages (stage III/IV) (70.2% vs 59.4%, p=0.042), though five-year RFS differences did not reach statistical significance (66.7% vs 53.8%, p=0.059). Similarly, non-epithelial subtypes (median follow-up 79 months; 95% CI: 54.2-103.8), demonstrated marked survival divergence (p<0.001 for OS and RFS); LG-ESS exhibited favourable outcomes (89.5% five-year OS, 80% five-year RFS), whereas HG-ESS (35.7% OS, 25% RFS) and LMS (30.8% OS, 16.3% RFS) demonstrated aggressive behaviour. Recurrence rates peaked in LMS (71.4%). Multivariable analysis identified curative-intent treatment as an independent predictor of improved OS (hazard ratio (HR): 0.33, 95% CI: 0.12-0.94, p=0.038). Time-dependent Cox regression revealed that disease recurrence markedly increased mortality hazard overall (HR: 18.9, 95% CI: 11.7-30.7, p<0.001), as well as within epithelial (HR: 16.4, p<0.001) and non-epithelial subgroups (HR: 33.7, p<0.001), with no significant interaction by histological class (epithelial versus non-epithelial; p=0.199) Interpretation and Conclusions: The relative frequency of epithelial subtypes mirrored global literature, whereas low-grade ESS and LMS occurred more frequently. Uterine SCs showed favourable early-stage survival, while local recurrences in LMS warrant multicentre evaluation.
Authors
- Karthickeyan Duraisamy (ORCID: https://orcid.org/0000-0003-2398-6418)
- Sairu Philip (ORCID: https://orcid.org/0000-0003-1531-9519)
- Mohandoss Murugesan (ORCID: https://orcid.org/0000-0002-8008-6953)
- Kalpita Samrat Shringarpure (ORCID: https://orcid.org/0000-0003-2203-9419)
- Arun P Narendran (ORCID: https://orcid.org/0000-0001-6901-0926)
- Greeshma K.E.
- Akhil Suresh
Institutions
- Malabar Cancer Centre (IN)
- Sir Sayajirao General Hospital Medical College (IN)
- Kannur Medical College (IN)
Publication Details
- Journal
- Cureus
- Published
- 2026-11-17
- DOI
- https://doi.org/10.7759/cureus.119849
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00